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AbsTrACT
Objective in this consensus statement, an international 
panel of experts deliver their opinions on key questions 
regarding the contribution of the human microbiome to 
carcinogenesis.
Design international experts in oncology and/or 
microbiome research were approached by personal 
communication to form a panel. a structured, iterative, 
methodology based around a 1-day roundtable 
discussion was employed to derive expert consensus on 
key questions in microbiome-oncology research.
results Some 18 experts convened for the roundtable 
discussion and five key questions were identified 
regarding: (1) the relevance of dysbiosis/an altered gut 
microbiome to carcinogenesis; (2) potential mechanisms 
of microbiota-induced carcinogenesis; (3) conceptual 
frameworks describing how the human microbiome may 
drive carcinogenesis; (4) causation versus association; and 
(5) future directions for research in the field. the panel 
considered that, despite mechanistic and supporting 
evidence from animal and human studies, there is currently 
no direct evidence that the human commensal microbiome 
is a key determinant in the aetiopathogenesis of cancer. 
the panel cited the lack of large longitudinal, cohort 
studies as a principal deciding factor and agreed that 
this should be a future research priority. However, while 
acknowledging gaps in the evidence, expert opinion was 
that the microbiome, alongside environmental factors and 
an epigenetically/genetically vulnerable host, represents one 
apex of a tripartite, multidirectional interactome that drives 
carcinogenesis.
Conclusion Data from longitudinal cohort studies are 
needed to confirm the role of the human microbiome as 
a key driver in the aetiopathogenesis of cancer.
InTrODuCTIOn
The last decade has seen a surge in the number of 
studies of the gut microbiome and cancer, facilitated 
by next-generation sequencing platforms, ‘omics’ 
technologies and advanced bioinformatics approaches. 
In contrast to the human genome which is inherited, 
largely static and which consists of approximately 
20 000 genes, the human microbiome is acquired, 
changes dynamically throughout life and contains 
approximately 10 to 20 million non-redundant genes.1 
The human microbiota was once viewed as comprising 
either pathogens, causing infectious disease, or passive 
bystanders. In appreciating the beneficial functions of 
commensal microorganisms, we have departed from 
this dichotomy to embrace a novel, subtler paradigm 
in which host microorganisms contribute to both 
physiology and pathology. Commensal microorgan-
isms, by definition, do not harm their host. Similarly, 
pathogens are defined by their ability to cause disease. 
significance of this study
What is already known on this subject?
 ► Putative pathogens such as human papilloma 
virus and Helicobacter pylori have been 
demonstrated to be aetiological agents in a 
variety of cancers.
 ► Humans possess anatomic niche-specific 
microbiomes which are involved in key aspects 
of host physiology and pathology.
 ► Data from in vitro, animal and human studies 
suggest that the human microbiome may be 
involved in the aetiopathogenesis of cancer.
What are the new findings?
 ► This is the first published expert consensus on 
the role of the microbiome in cancer.
 ► Experts considered that there is currently no 
direct evidence that the human commensal 
microbiome is a key determinant in the 
aetiopathogenesis of cancer.
 ► However, expert opinion was that the 
microbiome is one apex of a tripartite, 
multidirectional interactome alongside 
environmental factors and an epigenetically/
genetically vulnerable host that combine to 
cause cancer.
How might it impact on clinical practice in the 
foreseeable future?
 ► Clinicians should appreciate the current status 
of microbiome research with regards to the 
aetiology of cancer as it seems likely that 
manipulation of the microbiome may offer 
a therapeutic strategy for the prevention or 
treatment of cancer.
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However, we now appreciate that there is a large and poorly defined 
middle ground occupied by ‘pathogens’ coexisting with a disease 
free-host (eg, Helicobacter pylori) and the so-called ‘commen-
sals’ that may contribute to disease under certain conditions. This 
article is principally concerned with the latter cohort, which may 
be considered dynamic symbionts—a group of organisms whose 
symbiotic nature may vary along a spectrum from mutualism and 
commensalism to parasitism and amensalism. For simplicity, we will 
refer to this group of dynamic symbionts as the human microbiome 
(figure 1).
Genetic and environmental factors do not fully explain individual 
cancer risk—why do some (largely genetically identical) individuals 
who have similar lifestyles and ages get cancer while others do not? 
The random distribution of DNA replicative errors is part of the 
explanation,2 but the significant interindividual variation in micro-
biome composition and function, coupled with known and emerging 
potentially carcinogenic microbial-host interactions, suggest that 
the human microbiome may also be an important cofactor driving 
cancer risk. Evidence supporting this hypothesis has begun to accu-
mulate and, furthermore, the human microbiome appears to have 
importance in relation to cancer prognosis3 and treatment.4
The International Cancer Microbiome Consortium (ICMC) was 
established in 2017 in recognition of the emerging significance of 
the human microbiome in oncology. The ICMC comprises academic 
and clinical experts in oncology and the microbiome and its aim is 
to promote education and international research collaboration. In 
its inaugural meeting, ICMC hosted a 1-day roundtable discussion 
to draw together current research and establish an expert consensus 
regarding the role of the human microbiome in carcinogenesis.5 Key 
topics (figure 2) were identified and debated before generating the 
written document, which was subsequently revised by experts to 
produce the final consensus.
MeTHODs
The aim of this consensus statement was to perform a qualitative 
assessment of the current evidence relevant to the hypothesis that 
the human microbiome plays a causative role in the aetiopathogen-
esis of cancer. Discussion and conclusions were weighted towards 
bacteria (as opposed to viruses or fungi) because bacteria accounted 
for most of the available data. Discussion was not restricted to 
the gut and all cancer types were considered, though again, the 
gut microbiome and colorectal cancer (CRC) feature promi-
nently because of biases within the literature. Given that our aim 
was to convey current expert opinion on a novel area of science, 
as opposed to a specific clinical question, a structured, iterative, 
‘pseudo-Delphi’ methodology was employed rather than a formal 
Delphi methodology. This structured approach is summarised in 
figure 2. The core participants (AJS, JLA, CAM, JMK and JRM) 
identified contributors based on their expertise in the microbiome, 
surgical and medical oncology (upper and lower GI cancer, urolog-
ical cancers and oncogynaecology) and bioinformatics and invited 
them to contribute to the consensus by personal communication. 
Some 18 experts from Canada, China, Europe and the USA agreed 
to form the expert panel. In stage 1, panel members agreed, by 
email, on six key topics for discussion centred on the theme of the 
microbiome and carcinogenesis. In stage 2, panel members were 
assigned to each of these topics according to their expertise and led 
the debate and discussion on each topic during a 1-day face-to-face 
roundtable discussion which was recorded and minuted. In stage 3, 
the core participants reviewed the discussion and distilled it into five 
key questions to be addressed in the consensus statement. These key 
questions reflect the roundtable discussion rather than the a priori 
identified topics directly and were chosen because of their perceived 
interest to the academic and clinical community and their depth of 
discussion during the face-to-face meeting:
1. How does the concept of ‘dysbiosis’ relate to carcinogenesis?
2. What are the broad molecular mechanisms by which the hu-
man microbiome may be involved in the aetiopathogenesis 
of cancer?
3. What are the conceptual frameworks that best describe the 
promotion of carcinogenesis by the human microbiome?
4. Is the relationship between the human microbiome and the 
aetiopathogenesis of cancer causative or associative?
5. What are the key future directions for research in this field?
Extensive quotes from the discussion are available (see supple-
ment) while selected quotes are included in figures alongside the 
discussion pertaining to each key question (figures 3–7). In stage 4, 
the core participants drew on the roundtable debate and suggested 
literature to draft statements and supporting discussion in response 
to each key question. Statements were distributed electronically to 
the expert panel who rated the strength of evidentiary support and 
their personal level of agreement with each statement according to 
Likert scales (figure 2, stage 5). Some 16 (out of the 18 present at the 
panel discussion) experts responded and statements were assigned 
the modal response (number given in brackets, see supplement for 
full responses). Panel members also had the opportunity to revise 
the content of the consensus statement. During stage 6, the expert 
panel reviewed and revised the manuscript to arrive at consensus 
over multiple iterations.
resulTs AnD DIsCussIOn
Question one: How does the concept of dysbiosis relate to 
carcinogenesis (table 1)?
Table 1 How does the concept of dysbiosis relate to 
carcinogenesis?
statement evidentiary support
expert 
agreement
With respect to carcinogenesis, ‘dysbiosis’ 
should be considered a persistent departure 
of the host microbiome from the health-
associated, homeostatic state, towards 
a cancer promoting and/or sustaining 
phenotype.
Weak evidence from 
human studies (9)
Agree (10)
At the present time, there is no accepted 
quantitative definition of a ‘normal’ 
microbiome.
Strong evidence from 
human studies (7)
Agree (8)
Figure 1 Key terms in the microbiome literature.
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When considering the influence of the microbiome on disease 
states,6 the term dysbiosis is frequently invoked within the micro-
biome literature and is mostly based on ‘relative abundance’ 
inferred from 16S rRNA gene sequencing data. However, the 
term is often loosely applied, poorly defined and has drawn crit-
icism from the scientific community.7 We therefore sought to 
address the concept of dysbiosis specifically within the context 
of carcinogenesis. Dysbiosis has been defined as an abnor-
mality—in composition and/or function—of the host symbiotic 
microbial ecosystem that exceeds its restitutive capacity and 
has negative effects on the host.8 However, dysbiosis is likely 
host specific and disease specific—a microbiome may be dysbi-
otic in one individual, but not in another and/or may promote 
one pathology, but not another. Therefore, dysbiosis is not an 
absolute and cannot be defined outside of the context of the host 
and the disease in question. The broad hypothesis that the expert 
consensus explored is that abnormalities in the host microbiome 
composition and/or function—or dysbiosis—are associated with 
the aetiopathogenesis of cancer. But how can we elucidate these 
Figure 2 A multistage, structured, iterative methodology was employed. ICMC, International Cancer Microbiome Consortium.
Figure 3 Select quotes on dysbiosis and the microbiome.
 o
n
 25 June 2019 by guest. Protected by copyright.
http://gut.bmj.com/
G
ut: first published as 10.1136/gutjnl-2019-318556 on 15 May 2019. Downloaded from 
4 Scott aJ, et al. Gut 2018;0:1–9. doi:10.1136/gutjnl-2019-318556
Gut microbiota
abnormalities when even consensus regarding what comprises 
a ‘normal’ microbiome remains elusive? For example, although 
there can be said to be a ‘core microbiome’ at the phylum level 
(consisting primarily of Bacteroidetes and Firmicutes), there is 
significant difference between apparently healthy individuals at 
lower taxonomic levels.9 We stress ‘apparently’ because the long 
lag time associated with the development of most cancers makes 
it difficult to be sure that an individual is as ‘healthy’ as they seem 
without long-term follow-up. Interindividual variation in micro-
biome composition far exceeds variation associated with a given 
disease state. Such compositional variation may arise from the 
degree of functional redundancy displayed by the microbiome. 
For example, numerous microorganisms can produce short 
chain fatty acids (SCFA, eg, butyrate)—harbouring any of these 
organisms may be considered normal. Conversely, some func-
tions are more conserved and may even be strain specific. 16S 
rRNA taxonomic profiling cannot resolve this detail and instead 
researchers are considering whether there is a core metagenome 
or metabolome.10
We suggest that such a functional approach is of more utility 
in discussing normality and dysbiosis. With respect to the aetio-
pathogenesis of cancer, we propose that dysbiosis should be 
considered a persistent departure of the host microbiome from 
the health-associated homeostatic state (consisting of mutualists 
and commensals), towards a cancer promoting and/or sustaining 
phenotype (parasitism or amensalism). This dysbiosis is specific 
to the individual and thus can only be defined by prospective 
longitudinal analysis. For example, based on the current litera-
ture, the health-associated gut microbiome can be said to have 
several core features. It is diverse, resilient to short-term envi-
ronmental pressures and has sufficient plasticity to adapt to the 
benefit of the host in the face of longer term pressures.11 The 
health-associated microbiome should synergise with the host 
to drive beneficial immune responses12 and metabolic mutu-
alism.13 Finally, the microbiome should have a tumour-suppres-
sant effect on the host.14 15 Departure from these core features 
can be considered dysbiotic and may have the potential to incite 
or sustain cancer. It should be noted that the health-associated 
microbiomes of other niches will have different core features.
Question two: What are the broad molecular mechanisms 
by which the human microbiome may be involved in the 
aetiopathogenesis of cancer (table 2)?
Table 2 What are the broad molecular mechanisms by which the 
human microbiome may be involved in the aetiopathogeneis of 
cancer?
statement: the mechanisms by which 
the microbiome may initiate and/or 
drive carcinogenesis can be classified 
into: evidentiary support
expert 
agreement
Genomic integration Strong evidence from human 
studies (9)
Agree (8)
Genotoxicity Evidence from animal 
studies (6)
Agree (9)
Inflammation Strong evidence from human 
studies (7)
Agree (8)
Immunity Evidence from animal studies 
(6)/weak evidence from 
human studies (6)
Agree (9)
Metabolism Strong evidence from human 
studies (7)
Agree (13)
 
At the molecular level, the mechanisms by which microorgan-
isms can contribute to carcinogenesis are multiple and varied and 
have been extensively discussed elsewhere.16 The mechanisms 
may broadly be categorised into genomic integration, genotox-
icity, inflammation, immunity and metabolism. Many of these 
mechanisms are likely not evolved to cause pathologies in the 
host but rather do so as collateral damage, as the organism opti-
mises its chances of survival. Ultimately, all mechanisms converge 
on a final common pathway of prolonged host cell survival, 
enhanced replicative capacity and dedifferentiation.
Genomic integration
Integration of microbial DNA into the host genome is a viru-
lence mechanism for multiple viruses that are causally associ-
ated with the development of cancer. Cervical cancer caused 
by human papilloma virus (HPV-16 and HPV-18) is a classic 
example. Insertion of two HPV genes, E6 and E7, into the host 
genome in cervical cells confers a survival advantage as their 
protein derivatives bind to and inactivate tumour-suppressor 
gene products (p53 and pRB).17 Note that this mechanism relies 
on transcription of viral proteins which exerts a carcinogenic 
effect on the host. This mechanism contrasts with insertional 
mutagenesis which describes the deregulation of host gene 
expression caused by insertion of the exogenous genetic mate-
rial. If the host genes in question are tumour suppressor genes or 
oncogenes, cellular transformation to an oncogenic phenotype 
can ensue. Insertional mutagenesis is commonly associated with 
retroviruses and has been proposed as contributing to the onco-
genicity of human T-cell lymphotrophic virus.18
Genotoxicity
Genotoxicity describes structural DNA damage, for example, 
strand breaks, adducts, deletions and rearrangements. If host 
DNA damage does not lead to cell death, it may affect tumour 
suppressor genes or oncogenes with carcinogenic effects. Cyto-
lethal distending toxin (CDT) and colibactin are two well-char-
acterised genotoxins. CDT is produced by Escherichia coli and 
Campylobacter jejuni (among others) and induces double-strand 
DNA breaks via its DNAse activity.19 CDT-deficient strains have 
attenuated carcinogenic potential in murine CRC models.20 
Members of the Enterobacteriaceae family can also produce coli-
bactin which induces DNA strand breaks and has been associ-
ated with human CRC.21 Aside from specific toxins, bacterial 
metabolites may also exert genotoxic effects. Reactive oxygen 
species (produced by Porphyromonas sp) and hydrogen sulphide 
(produced by Bilophila and Fusobacterium) are two examples 
that have been associated with colorectal neoplasia.22 23
Inflammation
Inflammation is a central feature of carcinogenesis regardless 
of the aetiological agent and is the principal oncogenic mecha-
nism underlying numerous well-defined, causal, microbial asso-
ciations with cancer.24 Microbial virulence factors induce chronic 
inflammation of host tissue, stimulating cellular proliferation 
Figure 4 Select quotes on mechanisms of microbiome-induced 
carcinogenesis. HPV, human papilloma virus.
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which can ultimately become deregulated and, combined with 
failure of apoptosis, result in a malignant phenotype.25 These 
effects may be mediated by microbial interaction with specific 
host cell intracellular signalling pathways. For example, Fuso-
bacterium nucleatum (F. nucleatum; associated with CRC) can 
induce activation of the nuclear factor-kB (NF-kB) pathway26 
while both F. nucleatum and Bacteroides fragilis possess viru-
lence factors which negatively regulate E-cadherin, activating 
WNT/β-catenin signalling and driving cell proliferation.27 28 
Enterotoxigenic B. fragilis (ETBF) secretes B. fragilis toxin and 
stimulates an TH-17/IL-17-dependent colitis and promotes 
tumourigenesis.29 In addition to direct, niche-organ-specific 
effects, there is also evidence that microbe-associated molecular 
patterns can induce proinflammatory effects in remote organs 
via their interactions with host pattern recognition receptors, 
such as toll-like (TLR) and nucleotide-binding oligomerization 
domain-like (NOD) receptors. Interaction between bacterial 
lipopolysaccharide and TLR4 results in the downstream activa-
tion of cell survival pathways and has been cited as a mechanism 
by which the intestinal microbiome may contribute to carcino-
genesis outside the GI tract.30
Immunity
The interactions between the human microbiota and the 
immune system are well documented and have significant 
implications for a wide range of pathologies from atopy and 
autoimmunity to cancer.31 32 The host immune system plays 
a key role in preventing carcinogenesis by inducing cell death 
in abnormal host cells with neoplastic potential. The micro-
biome may interfere with this process at multiple levels. HIV 
has tropism towards CD4+ T lymphocytes, impairing the host’s 
ability to detect potentially neoplastic cells and increasing the 
rate of carcinogenesis. F. nucleatum expresses the Fap2 cell 
surface protein which interacts with T and Natural Killer cells to 
supress antitumour cytotoxicity.33 Although the microbiota may 
suppress host immunity, in the healthy state, it is hypothesised 
that microbiota-immune crosstalk facilitates the maintenance of 
an immune ‘tone’ promoting basal anticancer immunosurveil-
lance. Various mechanisms are proposed including broadening 
the T cell receptor repertoire and enhancing the intensity of 
immune responses.34
Metabolism
In addition to the immune system, metabolism is the second 
key level at which the host and the microbiota interact.13 The 
human microbiome is replete with genes which influence the 
metabolism of dietary vitamins and nutrients, xenobiotics and 
host-derived compounds such as bile acids. Bacterial metabo-
lism appears to be a crucial cofactor that underpins the observed 
associations between diet and various cancers.35 Pertinent to 
CRC, gut bacterial fermentation of dietary fibre to SCFA, such 
as butyrate, is believed to play an important role in suppressing 
oncogenesis via its anti-inflammatory and antiproliferative 
effects.15 In contrast, bacterial metabolism of bile acids and 
proteins can result in the formation of carcinogenic aromatic 
amines and sulphides.35 The microbiome also plays a substan-
tial xenometabolic role which includes the formation of ulti-
mate carcinogenic end products, acetaldehyde production from 
alcohol for example.36 However, the effects of microbial metab-
olites are likely to be context dependent on host factors. For 
example, microbial butyrate production has been suggested to 
induce CRC in mice deficient in the MSH2 gene (which codes a 
protein playing a key role in DNA mismatch repair) by driving 
hyperproliferation of colonocytes.37
Question three: What are the conceptual frameworks that 
best describe the promotion of carcinogenesis by the human 
microbiome (table 3)?
Table 3 What are the conceptual frameworks that best describe 
the promotion of carcinogenesis by rhe human microbiome?
statement evidentiary support
expert 
agreement
With respect to the pathogenesis of CRC, ‘the 
driver–passenger’ model40 accounts for key 
observations from mechanistic studies and 
investigations of the on-tumour versus off-
tumour microbiome.
Weak evidence from 
human studies (9)
Agree (8)
The role of the microbiome in the 
aetiopathogenesis of cancer can be 
conceptualised as one apex of a tripartite, 
multidirectional interactome alongside 
the environment and an epigenetically/
genetically vulnerable host.
Weak evidence from 
human studies (7)
Strongly 
agree (9)
 
Traditional carcinogens are generally conceptualised as initi-
ating agents, causing DNA damage and inciting carcinogenesis. 
This conceptual framework can also be applied to well-estab-
lished microbial carcinogens which induce DNA damage either 
directly via genomic integration (eg, HPV) or indirectly via 
immunosuppression (eg, HIV) and/or chronic inflammation (eg, 
HCV). However, our understanding of how the dynamic symbi-
onts of the human microbiome may contribute to carcinogenesis 
is less well established and are largely drawn from the investiga-
tion of CRC. Based on in vitro and murine in vivo data, Sears 
and Pardoll proposed the ‘alpha-bug hypothesis’ in which key 
members of the host microbiome possess specific virulence traits 
that are both directly oncogenic and that also remodel the micro-
bial community towards an oncogenic phenotype.38 They cite 
ETBF as a candidate ‘alpha-bug’, causing colonic epithelial cell 
damage directly via B. fragilis toxin and indirectly by modifying 
mucosal immune function and intracellular signalling events.27 29 
In support of this hypothesis, investigators have demonstrated 
that high abundance of ETBF in colonic tissues is associated with 
early-stage carcinogenic lesions.39 However, numerous studies of 
the on-tumour microbiome show large variation and fail to find 
consistent overabundance of putative alpha bugs in carcinoma 
tissue. In recognition of this observation, Tjalsma et al proposed 
a refinement to the alpha-bug hypothesis dubbed the ‘driver–
passenger model’.40 They agreed that certain bacterial drivers 
(akin to alpha bugs) are responsible for the initial epithelial DNA 
damage that incites oncogenesis. However, they propose that 
the oncogenic process creates a unique tumour microenviron-
ment that favours the proliferation of opportunistic passenger 
Figure 5 Select quotes on conceptual frameworks describing 
microbiome-induced carcinogenesis.
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bacteria that gradually outcompete the driver species. Thus, the 
colorectal tumour microbiome undergoes a temporal evolution 
correlating with tumour stage. This hypothesis is supported by 
observational data regarding bacterial communities present on 
colorectal tumours of varying stages.41 42 The ‘driver–passenger 
model’ does not exclude bacterial passengers from playing an 
active role in cancer progression. Fusobacterium sp have been 
consistently found to colonise CRC tissue in numerous studies 
and represent an archetypal passenger bacterium.43 44 Colorectal 
tumours are rich in amino acids, an essential substrate for 
Fusobacterium sp,45 and express ligands for Fusobacterium sp 
cell-surface receptors of which may explain their overabun-
dance.46 Fusobacterium sp may also promote tumour progres-
sion via interactions with intracellular signalling pathways and 
immune cells.26 28
Although these models account for key observations from 
mechanistic studies and investigations of the on-tumour micro-
biome, they perhaps fall short of addressing the aetiopatho-
genesis of cancer at the macrolevel. For example, how do 
environmental exposures, such as diet, contribute to cancer risk? 
What is the impact of host genetic factors? Are these indepen-
dent risk factors for cancer development or do they act in consort 
with the microbiome? In consideration of these questions, we 
propose a broad framework for modelling the role of the micro-
biome in the development of cancer based on the concept of 
the interactome. In this model, we consider carcinogenesis to be 
the ultimate outcome from harmful, tripartite, multidirectional 
interactions between the microbiome, the environment and the 
epigenetically/genetically vulnerable host. The relative contribu-
tions of these three apices will vary among cancer subtypes. In 
the case of CRC, for example, it seems likely that the microbiota 
is necessary, but not sufficient for carcinogenesis; a hypothesis 
supported by chemical (environment)47 or genetic (vulnerable 
host)48 rodent models of CRC that display significantly attenu-
ated or no tumour development in germ-free settings. Bacterial 
driver functions (such as toxin, hydrogen sulphide or (reduced) 
butyrate production) are the key transducers of environmental 
cues (such as diet) that can incite carcinogenesis in a vulnerable 
host (eg, specific TLR genetic polymorphisms). Progression of a 
neoplasm may depend on continued exposure to environmental 
stimuli, maladaptive/adaptive changes in microbiome function 
and/or host response.
Question four: Is the relationship between the human 
microbiome and the aetiopathogenesis of cancer causative or 
associative (table 4)?
Table 4 Is the relationship between the human microbiome and 
the aetiopathogenesis of cancer causative or associative? 
statement evidentiary support
expert 
agreement
At the single-organism level, the role of 
microorganisms as aetiological agents in 
carcinogenesis is well established.
Strong evidence from 
human studies (10)
Strongly 
agree (8)
There are plausible mechanisms by which 
the human microbiome may cause cancer.
Evidence from animal 
studies (8)
Strongly 
agree (10)
There is a causal relationship between 
the human microbiome and the 
aetiopathogenesis of some cancers.
Weak evidence from 
human studies (8)
Agree (10)
 
Despite a re-evaluation that considered modern sequence-
based bacterial identification,49 Koch’s postulates cannot be 
applied to prove the causation of cancer by the host microbiome 
because it is not an ‘infectious agent’. The development of cancer 
is determined by the cumulative effects of a wide variety of risk 
factors and protective factors on an individual. Despite this 
complexity, at the single organism level, the role of microor-
ganisms as aetiological agents (or risk factors) in carcinogenesis 
is well established. Numerous viruses, including human herpes-
virus 8 select virotypes of HPV, hepatitis B and C, Epstein-Barr 
virus and HIV are classified as class 1 carcinogens by the Interna-
tional Agency for Research on Cancer (Lyon, France). H. pylori, 
schistosomes and liver flukes are also known to be carcino-
genic. Such causal relationships are founded on Bradford Hill’s 
criteria which can be broadly categorised as: direct evidence 
from studies that a relationship between an exposure and an 
outcome is causal; mechanistic evidence that connects the expo-
sure and outcome and parallel evidence that supports the causal 
relationship suggested in a study.50 For example, direct evidence 
for the causal relationship between H. pylori and gastric cancer 
(controversial for some time) comes from Uemura et al’s land-
mark prospective cohort study demonstrating that gastric cancer 
developed in approximately 3% of individuals infected with H. 
pylori compared with none of the uninfected individuals.51 This 
finding has been supported by numerous studies demonstrating 
mechanisms by which H. pylori contributes to gastric carcinogen-
esis including chronic inflammation and direct genotoxic effects 
mediated by a variety of defined virulence factors and effectors 
(eg, CagA, cagPAI and VacA).52 Parallel evidence comes from 
randomised trials demonstrating a reduction in the incidence of 
gastric cancer following H. pylori eradication.53 It is notable that 
not all individuals infected with H. pylori develop gastric cancer. 
Infection alone is not sufficient to cause disease; there are other 
factors which govern an individual’s susceptibility.
In contrast, a causal relationship between the human symbi-
otic microbiome and the development of cancer is not firmly 
established. The nature of the microbiome presents several chal-
lenges for proving causation. The microbiome—including the 
virome, mycobiome and other organisms—is orders of magni-
tude more complex than a discrete risk factor such as smoking or 
colonisation by a single organism. The microbiome is dynamic, 
changing with age, environmental exposures (eg, diet, antibiotics 
and some surgeries) and the development of cancer itself. While 
a causal relationship has been posited for numerous cancer 
types, the role of the gut microbiome in colorectal carcinogen-
esis has received the most attention and offers the strongest 
evidence. We have already summarised the mechanistic evidence 
supporting causation. Parallel evidence comes from murine 
studies in which germ-free mice chemically or genetically predis-
posed to intestinal neoplasia, develop fewer tumours compared 
with conventionally housed counterparts, while carcinogenesis 
can be potentiated by exposing mice to specific bacteria or stool 
Figure 6 Select quotes on the potential causal relationship between 
the human microbiome and carcinogenesis.
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from patients with CRC.26 54 Human studies have demonstrated 
that the CRC microbiome differs from that of nearby normal 
tissue with reduced diversity and altered community structure 
with lower relative abundance of potentially protective taxa 
(eg, butyrate-producing Roseburia) and increased abundance of 
taxa with potentially procarcinogenic phenotypes (eg, Fusobac-
terium, Bacteroides, Campylobacter, Escherichia and Porphyro-
monas).43 44 55–57 However, it is currently unclear whether this 
altered community structure is a risk factor for CRC develop-
ment or rather evolves secondarily to the unique tumour micro-
environment. Studies have shown a linear relationship between 
microbiome composition and tumour stage, moving through the 
adenoma-carcinoma sequence, and also with other histological 
tumour features such as lymphovascular and perineural inva-
sion.41 42 These findings are at least consistent with causation but 
could also be argued to reflect changes in the tumour microen-
vironment. However, uninvolved, normal colonic mucosa from 
patients with CRC also demonstrates taxonomic differences 
(eg, abundance of sulfidogneic Bilophila wadswothia) compared 
with healthy mucosa from controls suggesting a microenvi-
ronment-independent underlying field change.58 Nonetheless, 
direct evidence supporting causation in a human population is 
lacking as current studies have been cross sectional with single-
time-point sampling—there are no prospective, longitudinal 
data from large cohort studies. The evidence for other cancer 
types and microbiome niches is generally weaker than that for 
the gut microbiome and CRC and is therefore also unproven.
Question five: What are the key directions for future research 
to develop our understanding of the role of the microbiome 
in carcinogenesis (table 5)?
Table 5  What are the key directions for future research to 
develop our understanding of the role of the microbiome in 
carcinogenesis? 
statement: key areas for future development with 
respect to the investigation of the microbiome and 
carcinogenesis are: expert agreement
Large, international cohort studies Strongly agree (10)
Prospective longitudinal sampling Strongly agree (14)
More focus on interventional, rather than purely 
observational studies
Strongly agree (6)/agree 
(6)
Integration of microbiome analysis with other 
oncological research projects
Strongly agree (12)
Standardisation and transparency in reporting 
microbiome research
Strongly agree (10)
 
With the aims of making a more definitive statement regarding 
causality and generating true translational impact, the consor-
tium suggested several key directions for future work on the 
microbiome and cancer.
Large, longitudinal international cohort studies
Proving causation in cancer is difficult because of the lag 
between exposure and phenotype and the complex interactive 
nature of potential causative factors. However, these difficulties 
can be overcome by conducting large, international, longitudinal 
cohort studies as exemplified by the European Prospective Inves-
tigation into Cancer and Nutrition (EPIC)59 and Framingham60 
studies. The execution of such studies within the microbiome 
field is not without challenge61 but is necessary to move from 
testing association to causation.
Increased focus on interventional studies
Observational studies have provided valuable knowledge 
regarding microbiome composition and function in cancer but 
if we are to translate this to patient benefit, more emphasis must 
be placed on interventional research. We need to develop our 
understanding of how manipulation of the microbiome can 
impact cancer. For example, early studies have suggested that 
antibiotic use may increase cancer risk.62
Integration with other oncology research
One way in which to deliver the above three goals is to 
consider the integration of microbiome research into oncology 
studies and trials. It is relatively common for clinical trials to 
have a basic/translational aspect that frequently delves into mech-
anistic aspects of disease. Given the potential involvement of 
the host microbiome in the aetiopathogenesis of cancer, cancer 
diagnosis as well as the efficacy and toxicity of chemotherapy, 
immunotherapy and radiotherapy, microbiome analysis would 
be a pertinent angle of inquiry in many oncology trials. Primary 
or secondary cancer prevention studies with interventions such 
as dietary change are prime examples.
Standardisation and transparency in reporting microbiome 
research
Microbiome science has captured the imaginations of scien-
tists, clinicians and the public alike but often blinds consumers 
with complex ‘omics’ methodologies while simultaneously 
failing to deliver on its translational potential. This has precip-
itated criticism of the entire field63. Reporting guidelines have 
become de rigueur in many aspects of basic and clinic research 
and the panel would welcome the application of similar frame-
works to microbiome research. Transparent reporting of exper-
imental and analytical methods alongside detailed metadata is 
essential to facilitate reproducibility.
COnClusIOn
In this consensus statement, we have reflected on current expert 
opinion regarding the crucial question of whether the human 
microbiome plays a causative role in the aetiopathogenesis of 
cancer, with a focus on CRC. While cancer causation by specific 
microorganisms (such as H. pylori) is beyond doubt, proving 
causation for the human microbiome in the broader sense is more 
challenging. There are plausible mechanisms and ample parallel 
or supporting evidence from in vitro, murine and cross-sectional 
human studies. However, direct evidence from large longitudinal 
cohort studies is lacking and should be a key focus in the future. 
Until then, the expert panel considers that the case in support 
of a causative role for the human microbiome in the aetiopatho-
genesis of cancer remains unproven, but a majority nevertheless 
agrees with the hypothesis. The panel considers the microbiome 
to be one aspect of an interactome with an epigenetically/genet-
ically vulnerable host and the environment. However, the host 
genotype is largely fixed and evidence suggests that the micro-
biome may be a key player in modulating/mediating the response 
to environmental pressures. In this context, the microbiome 
Figure 7 Select quotes regarding future directions in the field.
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presents a very exciting opportunity to better understand cancer 
and how it might be prevented.
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